COMPANY

Founder/Chief Genomics Officer

Young Seok Ju, M.D., Ph.D., is a Genomics co-founder of Genome Insight and brings expertise in genome technologies, bioinformatics, and cancer genomics to the company. 

He started whole-genome analyses in 2007, completing the first Korean whole-genome sequence analysis (Nature 2009). Young explored cancer genomes and revealed KIF5B-RET fusion oncogene (Genome Res 2011), clonal evolution of lung adenocarcinomas to small-cell carcinomas (J Clin Oncol 2017), complex genomic arrangements underlying fusion oncogenes (Cell 2019), and cancer mitochondrial DNA mutations (Nature Genetics 2020). He is also an Associate Professor at KAIST, directing the Center for Somatic Mutation and Mosaicism (SMM).

Chief Executive Officer

Jehee serves as the CEO of Genome Insight Inc. With over twenty years of experience as a business leader in the life-sciences industry, he brings a wealth of knowledge and expertise to the role. Prior to his current position, Jehee held CEO and senior executive roles at various biotech companies where he managed both early stage and clinical assets. He also worked as a brand manager at Novartis and served as a Partner at McKinsey & Company, advising top-tier life-sciences leaders.

Chief Medical Science Officer

Dr. Erin Connolly-Strong serves as the Chief Medical Science Officer at Genome Insight, leveraging expertise in medical affairs, clinical study design, and market access strategy. With a Ph.D. in Biomedical Science and a wealth of experience in pharmaceuticals and diagnostics, Erin is dedicated to furthering Genome Insight's mission of revolutionizing precision medicine and biomedical research via innovative data analytics and novel insights.

Chief Clinical Operations Officer

As the Chief Clinical Operations Officer, Stephanie brings over 15 years of clinical laboratory experience to Genome Insight. Prior to her current role, Stephanie has successfully led teams to develop and implement multiple next generation sequencing assays, specializing in oncology.

Chief Technology Officer

Sangmoon Lee, M.D., Ph.D., is the Chief Technology Officer at Genome Insight Inc., specializing in cancer genomics and rare disease genetic diagnostics using whole genome sequencing. With a background as a medical doctor and postdoctoral training in rare disease genetics at UC San Diego, Dr. Lee brings valuable knowledge in human genetics, genomics, and bioinformatics to the team. Genome Insight utilizes a big data lake to generate new insights, which Dr. Lee is dedicated to advancing.

Chief Informatics Officer

Won-Chul Lee is driving the company's research and development efforts in the area of advanced computational methods and tools for analyzing complex cancer genome data. Before joining Genome Insight, Won-Chul worked as a Senior Computational Biologist at Pfizer Oncology Research & Development, where he led projects focused on identifying new drug targets through the analysis of multi-omics preclinical and clinical data. 

Won-Chul earned his PhD in the College of Medicine at Seoul National University and completed a postdoctoral training program at The University of Texas MD Anderson Cancer Center, where he studied cancer evolution and the mechanisms of metastasis.

Founder/Chief Executive Officer

Jeong Seok (Jeong) LEE is the co-founder of Genome Insight, and currently serves as CEO of the Korean company Genome Insight. With a diverse background in academia and industry, as a trained internist, rheumatologist, and immunologist, he is an experienced medical professional and scientist. He received his medical degree at Seoul National University College of Medicine, and his Ph.D. in human T cell immunology at KAIST.

Chief Legal Officer

Min-Ho KIM is the Chief Legal Officer at Genome Insight with over 14 years of legal experience. With his educational background and professional experience, he manages the intricate matters of Genome Insight where science, technology and law are intertwined. 

Prior to joining the company, as a patent attorney, he has advised clients on establishing a strong patent portfolio and also played a crucial role in multi-jurisdictional patent disputes within the ICT industry. Min-Ho holds an LL.M. from the University of Southern California and is admitted to the Illinois bar and the Korean patent bar.

Chief Medical Officer

Dr. Oh, the Chief Medical Officer at Genome Insight, Inc., leads clinical studies that utilize whole genome sequencing for the purpose of collecting clinico-genomic data and is responsible for introducing whole genome sequencing to the routine care of patients with cancer and rare diseases. 

During his career as an assistant professor at Seoul National University Hospital, he treated patients with hereditary retinal diseases and ophthalmic tumors and participated in several clinical development of medical devices and pharmaceutical agents.

Chief Genomic Operation Officer

Jong Yeon (Anna) Shin joined Genome Insight as a Chief Genomic Operation Officer and has led genomics platform execution and operation. Prior to joining Genome Insight, she was at Macrogen for 10 years, serving in roles including Senior Vice President, Division Manager for Clinical Diagnosis, Vice President Division Manager for Technology Innovation, and Director for Precision Medicine Institute. Under Shin’s guidance, the Genomics Platform operated as one of the largest sequencing centers in the world, exploring, validating, optimizing, and implementing new technologies, and methods.

Chief Information Officer

Junggil (Gili) PARK has over 24 years of experience in the IT field. For 20 years, he worked as a product owner responsible for the design/development/project/maintenance of two products related to the port logistics system at a large Korean company. After that, at the Korean Research Institute of DPW, a global port operator, he was responsible for the port automation system product owner for three years. He joined Genome Insight in 2022 and is responsible for IT Center operations and IT products.

Chief Technology Officer

Ryul Kim, the Chief Technology Officer, is a highly accomplished bioinformatics professional. With a PhD from KAIST and a Master's Degree from Seoul National University, Ryul brings extensive clinical research experience from his time as a clinical fellow at Samsung Medical Center. 

As the Head of Analytical Platform Center at Genome Insight in Korea, he leads a team of experts in developing innovative tools and techniques to extract valuable insights from genomic data. Ryul's diverse background in medicine and engineering, combined with his expertise in bioinformatics, drives the advancement of genomics and bioinformatics for both Genome Insight and the wider scientific community.

Chief Executive Officer

Stephanie is a healthcare professional with over 10 years of experience in strategic planning, consulting, and business development. She currently serves as the CEO of Genome Insight Hong Kong Ltd., where she spearheads growth and development initiatives. Stephanie's focus on leveraging technology and innovation to improve patient outcomes has driven the company's success. 

Her previous experience in strategic planning at Samsung Group allowed her to advise executives on global healthcare strategy and business development. She has collaborated with healthcare providers, research institutions, and other industry players to develop joint initiatives that benefit all parties. Stephanie holds an MBA degree from Korea University.

Chief Research Officer

June-Young Koh is the Chief Research Officer at Genome Insight, Inc. with a background as a pediatrician and a PhD in Immunology. He has extensive clinical experience and has published research on altered cellular responses in critically ill patients with rare diseases. Leveraging his expertise in clinical management and basic science, he is focused on advancing genomic research to uncover innovative solutions for patients with rare diseases and cancer. With a commitment to advancing genomic research, he contributes valuable expertise to Genome Insight and is dedicated to improving patient outcomes.